Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multiple-Center, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of Oral NRX 194204 Capsule Administered Daily for a Minimum of 4 Weeks in Patients With Refractory Malignancies

NCT00630760 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT00630760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00630760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multiple-Center, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of Oral NRX 194204 Capsule Administered Daily for a Minimum of 4 Weeks in Patients With Refractory Malignancies
Lead sponsor
University of Southern California
Phase
Phase 1
Overall status
Terminated
Start date
February 29, 2008
Completion date
June 30, 2010
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory malignancies